Aeglea raises $50M in IPO after slashing share price

John Carroll Austin, TC-based Aeglea BioTherapeutics raised $ 50 million in its IPO after pricing 5 million shares at $ 10 each, far below the range that it had set out for itself. FierceBiotech ...

Novo Nordisk rolls out long-awaited Tresiba, aiming for blockbuster market share

Tracy Staton Novo Nordisk finally launched its next-gen diabetes treatment Tresiba in the U.S., approved by the FDA last September. The Danish drugmaker has high hopes ...

Boehringer wins FDA approval for its Pradaxa antidote with eyes on a bigger market share

Damian Garde Boehringer Ingelheim picked up an FDA nod for an injection designed to reverse the effects of its blockbuster anticoagulant Pradaxa, marking the first approval for an antidote ...

Bayer, Merck KGaA spend big bucks for market share in China

Carly Helfand Multinational pharma companies have been targeting China for years with an eye on its aging population, expanding middle class and growing incidence of chronic maladies ...

Big Pharma to share abandoned drugs, Actelion M&A rumors resume, Gaza war threatens IPOs

Nick Paul Taylor In this week's EuroBiotech Report, events in Gaza and Ukraine have cast a shadow over Europe, with sections of the Israeli biotech industry among the many groups ...

Actavis cans 190 Forest workers while 6 execs share up to $186M in deal ‘awards’

Eric Palmer There are winners and losers in mergers, and as a general rule, executives win and at least some workers lose. That certainly is the case with Actavis and Forest Laboratories. ...

New data positions Astellas prostate cancer med Xtandi to grab market share from J&J’s Zytiga

Tracy Staton Some new data on the prostate cancer drug Xtandi promises to heat up competition with Johnson & Johnson's Zytiga. Medivation and its partner Astellas Pharma unveiled ...

Indian drugmakers grab big share of U.K. pharma market

Tracy Staton In the U.K., drugs produced in India are almost as common as those made in Britain, a new report from the Medicines and Healthcare Products Regulatory Agency says. FiercePharma ...

Branded or Generic? Adults Share Preferences in Study

mia.burns By Mia Burns (mia.burns@ubm.com) Close to 16 percent, or 37 million of adults agree that paying more for branded prescription medications rather than getting generic products, ...

After Bristol-Myers R&D cuts, will AstraZeneca amp up its share of diabetes JV?

Tracy Staton When Bristol-Myers Squibb reported earnings last week, it seemed fully committed to AstraZeneca and their multibillion-dollar diabetes joint venture. Sales growth there ...

Celltrion CEO faces investigation of share manipulation

John Carroll Just months after winning European approval for a biosimilar of Remicade, Korea's Celltrion says its CEO–and largest shareholder–faces a formal investigation ...

M&A buzz: ViroPharma could go for $60 per share in buyout

Ryan McBride The rare-disease drug specialist ViroPharma has been generating buyout buzz all week after reports that the company brought on the services of Goldman Sachs to hunt for ...
Page 1 of 212
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS